Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1026706 in Healthy Male Smokers
NCT02657408Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing BI 1026706 with Placebo (2 arms). Primary endpoint: Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid at Day 29. Started Mar 2016; status: completed.
02
Drugs
BI 1026706
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02657408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657408.